MOTS-c and metabolism: promising in mice, unproven in people

What MOTS-c is

Most of the proteins in your body are coded by DNA in the cell nucleus. Mitochondria, the cell's energy factories, carry their own small genome, and in 2015 researchers reported that it codes for a 16-amino-acid peptide they named MOTS-c. It belongs to a family called mitochondrial-derived peptides, which act as signals between mitochondria and the rest of the cell, and possibly the rest of the body.

MOTS-c circulates in the blood, and the 2021 Nature Communications study found that levels in muscle rise sharply after exercise. That placed it in the middle of research on metabolism and aging.

How it is thought to work

In the original mouse and cell work, MOTS-c appeared to act mainly on skeletal muscle, the body's largest consumer of glucose. It interfered with the folate cycle, which led to a build-up of a molecule that activates AMPK. AMPK is the same energy sensor that exercise switches on, and that metformin influences indirectly. Under metabolic stress, MOTS-c also seemed to move into the cell nucleus and affect stress-response genes.

These mechanisms are biologically coherent, but they come from cells and mice. They have not been confirmed by giving MOTS-c to people and measuring the same pathways.

What the animal research found

• Mice fed a high-fat diet and given MOTS-c gained less weight and developed less insulin resistance than untreated mice
• Treatment improved how muscle handled glucose
• In the 2021 study, injections in aged mice improved physical function and reduced fat mass
• Long-term safety and effects on other organs were not the focus of these studies

The human evidence, honestly

Human data so far fall into two groups. Observational studies compare natural MOTS-c levels between people with and without conditions such as obesity or diabetes, and genetic studies have linked a variant in the MOTS-c sequence, common in some East Asian populations, with metabolic traits. Neither design can show that taking MOTS-c helps.

No randomized controlled trial has shown that MOTS-c injections lower A1c, improve insulin sensitivity or cause weight loss in people. In its own safety review, the FDA said it has identified no human exposure data for MOTS-c and noted possible immunogenicity risk and impurity concerns for certain routes.

What the July 2026 committee vote means

MOTS-c had been placed in Category 2 of the FDA's interim compounding lists and was moved to the nominated-but-withdrawn list in April 2026. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 7 to 5, with two abstentions, to recommend MOTS-c for the 503A bulks list for proposed uses in obesity and osteoporosis. FDA staff had recommended against adding it.

The committee is advisory, and its votes are non-binding. The FDA must still complete notice-and-comment rulemaking, which had not happened as of October 2026. A vote about whether pharmacies may compound a substance is not evidence that it works, and MOTS-c is not FDA-approved for any use.

Why mouse results often do not carry over

Mice burn energy much faster than people, live a fraction as long, and in metabolic studies are often fed diets designed to make them gain weight quickly. A compound that blunts that rapid weight gain may not do the same in a person whose insulin resistance developed over decades. Doses, routes and how quickly a peptide is broken down can also differ widely between species. Many metabolic compounds that looked strong in mice have not worked in human trials, which is why the human step cannot be skipped.

Is MOTS-c like metformin?

They touch some of the same pathways, which is why the comparison comes up. The difference is the evidence. Metformin is FDA-approved for type 2 diabetes, has decades of safety data, and in the NIH-funded Diabetes Prevention Program it lowered the risk of developing type 2 diabetes by 31 percent in adults with prediabetes. MOTS-c has nothing comparable in people.

What to do first about insulin resistance

• Get the basics measured: A1c and fasting glucose, with lipids and liver tests where appropriate
• Build regular aerobic activity and strength training into your week; the DPP lifestyle program cut diabetes risk by 58 percent
• Aim for modest weight loss if you carry extra weight; 5 to 7 percent can make a real difference
• Look at sleep, alcohol and medicines that raise blood sugar
• Discuss proven medicines such as metformin or, when criteria are met, GLP-1 medicines

If you still want to consider MOTS-c

A HealifyMD clinician can discuss MOTS-c as an experimental option after reviewing your labs, medicines and goals. It is prescribed only when appropriate and only if a licensed pharmacy confirms it can lawfully dispense it. HealifyMD MOTS-c is a compounded preparation from a licensed U.S. pharmacy; compounded medicines are not FDA-approved, and we do not publish home dosing. The price is from $275/month, or $500 for 2 months ($250/month), confirmed at your eligibility review, with labs priced separately.